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Evolving Role of Vorinostat Combined with 
Radiation Therapy in the Treatment of Brain 
Tumors, from the Lab to the Clinic
Purpose/Objective(s)
Radiation therapy (RT) is a critical element in the treatment of both 
brain metastases and glioblastoma (GBM). Temozolomide (TMZ) has 
an established role in the upfront treatment of GBM. Down-regulated 
mismatch repair (MMR) is a known mechanism of resistance to 
TMZ. Vorinostat (SAHA), an HDAC inhibitor, has successfully been 
combined with a number of cytotoxic agents, including ionizing 
radiation (IR). We performed a series of preclinical and clinical 
studies to examine the role of SAHA in the treatment of brain tumors.
Material/Methods, Preclinical
Experiments were performed with 2 GBM cell lines. DNA double 
strand breaks were quantified by both neutral-comet assay and 
gamma-H2AX immunohistochemistry. For the neutral comet assay 
the ‘olive moment’ represents DNA damage. For gamma-H2AX 
assay, the percentage of cells with more than 3 foci was scored.
Methods, Clinical
A multicenter dose-escalation phase I trial, based on Fibonacci 3+3 
design is being conducted. Whole-brain radiation is delivered in 
daily fractions of 2.5 Gy over 3 weeks (total dose 37.5 Gy). Vorinostat 
is delivered once daily on days of radiation therapy. Dose levels: 
increase from 200 mg PO qd to 400 mg PO qd in subsequent cohorts. 
Expected total accrual: 9-18 patients. Primary endpoint: tolerability.
Results, Preclinical
In the absence of drug, radiation-induced DNA-double strand breaks 
were almost completely repaired within 24-hours. Both TMZ + IR, 
and SAHA + IR increased the olive moment compared to IR alone (24 
hour post IR time-point). Surprisingly, when TMZ and SAHA were 
combined together with IR, the olive moment decreased to 6.5 as 
compared to TMZ + IR alone 8.7 (p<0.05). Similarly, in the absence of IR, 
SAHA was found to decrease TMZ-induced DNA damage. Comparable 
results were obtained with gamma-H2AX assay and with the 2nd cell 
line. On qPCR, SAHA decreased expression of key genes involved in 
MMR. Despite this, clonogenic radiation survival assays demonstrated 
TMZ + SAHA to be more effective than TMZ alone in potentiating 
the cytotoxic effect of IR.
Results, Clinical
Initial results indicate that low dose Vorinostat combined with RT is 
well tolerated, dose escalation is continuing.
Conclusion
SAHA shows promise as a radiosensitzer for brain tumors. The 
discrepancy between DNA-damage and clonogenic-cell-survival 
assays suggests that SAHA’s mechanism of radiosensitization may 
involve more than potentiation of DNA-damage. The efficacy 
of Vorinostat combined with temozolomide requires further 
investigation. Future clinical trials will investigate short-course dose-
escalated drug schedules.
Lawrence, Y.R., Wachsberger, P., Liu, Y., Andersen, B., Dicker, A.P.
1Department of Radiation Oncology, Thomas Jefferson University Hospitals, Philadelphia, PA
ASTRO Annual Meeting
